Dr. Owen has a long-standing interest in the diagnosis, treatment, and laboratory assessment of response in Waldenström’s macroglobulinemia (WM), myeloma, and related plasma cell disorders, including minimal residual disease in myeloma. With colleagues, he has developed a disease-specific assay for WM.

Dr. Owen studied medicine at the University of Wales College of Medicine, qualifying in 1988. He gained his MRCP from the Royal College of Physicians, London, in 1991, and his FRCPath from the Royal College of Pathologists, London, in 1998. In 2001, he completed a research/training fellowship in hematopathology, and since 2001 he has been a consultant in clinical hematology and hematopathology at Leeds Teaching Hospitals NHS Trust.

Dr. Owen has developed national and international treatment guidelines in WM, has led consensus groups in developing diagnostic and treatment response criteria, and has been the principal investigator of randomized studies in WM and myeloma.